APLTApplied Therapeutics Inc.

Nasdaq www.appliedtherapeutics.com


$ 5.77 $ 0.17 (3.04 %)    

Friday, 23-Aug-2024 15:59:46 EDT
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.00 $ 5.91 (1.06 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 5.77
$ 5.76 x 200
-- x --
-- - --
$ 1.22 - $ 9.39
886,037
na
662.66M
$ 1.32
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-06-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-23-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-10-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-11-2021 03-31-2021 10-Q
15 03-18-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-11-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-13-2020 12-31-2019 10-K
20 11-13-2019 09-30-2019 10-Q
21 08-12-2019 06-30-2019 10-Q
22 06-21-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rare-disease-focused-applied-therapeutics-lead-candidate-govorestat-has-blockbuster-potential-analyst-sees-140-stock-upside

William Blair has initiated coverage on Applied Therapeutics highlighting its focus on rare diseases such as galactosemia, SORD...

 william-blair-initiates-coverage-on-applied-therapeutics-with-outperform-rating

William Blair analyst Tim Lugo initiates coverage on Applied Therapeutics (NASDAQ:APLT) with a Outperform rating.

 rbc-capital-reiterates-outperform-on-applied-therapeutics-maintains-12-price-target

RBC Capital analyst Brian Abrahams reiterates Applied Therapeutics (NASDAQ:APLT) with a Outperform and maintains $12 price t...

 rbc-capital-reiterates-outperform-on-applied-therapeutics-maintains-12-price-target

RBC Capital analyst Brian Abrahams reiterates Applied Therapeutics (NASDAQ:APLT) with a Outperform and maintains $12 price t...

 fda-presses-delay-button-for-applied-therapeutics-first-potential-marketed-drug-for-rare-disease

FDA extends the review period for Applied Therapeutics' NDA for govorestat, targeting Classic Galactosemia treatment. The n...

 why-doma-holdings-shares-are-trading-higher-by-around-34-here-are-20-stocks-moving-premarket

Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transa...

 oxford-industries-posts-weak-results-joins-applied-therapeutics-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

U.S. stock futures were higher this morning, with the Dow futures gaining by over 100 points on Monday.

 applied-therapeutics-says-fda-has-extended-review-period-for-nda-for-govorestat-at-007-for-treatment-of-classic-galactosemia-by-three-months-pdufa-target-action-date-november-28-2024

The FDA notified Applied Therapeutics that it required additional time to review supplemental analyses of previously submitted ...

 rbc-capital-initiates-coverage-on-applied-therapeutics-with-outperform-rating-announces-price-target-of-12

RBC Capital analyst Brian Abrahams initiates coverage on Applied Therapeutics (NASDAQ:APLT) with a Outperform rating and ann...

 applied-therapeutics-files-prospectus-for-disposition-from-time-to-time-by-selling-stockholders-of-up-to-143m-shares-of-common-stock

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION